<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363813">
  <stage>Registered</stage>
  <submitdate>5/03/2013</submitdate>
  <approvaldate>6/03/2013</approvaldate>
  <actrnumber>ACTRN12613000272796</actrnumber>
  <trial_identification>
    <studytitle>Does Caralluma fimbriata extract (Slimaluma) combined with Morosil extract reduce the risk factors of metabolic syndrome in overweight and obese adults?</studytitle>
    <scientifictitle>The effect of Caralluma fimbriata extract combined with Morosil extract on the risk factors of metabolic syndrome in overweight and obese adults: a randomised controlled clinical trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Group 1: Placebo group + nutrition advice: Participants will take one 500mg capsule (containing maltodextrin/Placebo) and one 250mg capsule (containing maltodextrin/placebo) orally 30 minutes before meals twice daily for 16 weeks. Participants will also receive nutrition advice in a one on one nutrition consultation with a nutritional therapist for 30-45 minutes, fortnightly for 16 weeks. The recommendations will be based on the Australian Dietary Guidelines for Adults. 

Group 2: Caralluma fimbriata + nutrition advice group: Participants will take one 500mg capsule (containing Caralluma fimbriata extract) and one 250mg capsule (containing maltodextrin/placebo) orally 30 minutes before meals twice daily for 16 weeks. Participants will also receive nutrition advice in a one on one nutrition consultation with a nutritional therapist for 30-45 minutes, fortnightly for 16 weeks. The recommendations will be based on the Australian Dietary Guidelines for Adults.

Group 3: Morosil + nutrition advice group: Participants will take one 500mg capsule (containing Maltodextrin/ Placebo) and one 250mg capsule (containing Morosil extract) orally 30 minutes before meals twice daily for 16 weeks.  Participants will also receive nutrition advice in a one on one nutrition consultation with a nutritional therapist for 30-45 minutes, fortnightly for 16 weeks. The recommendations will be based on the Australian Dietary Guidelines for Adults.

Group 4: Caralluma fimbriata + Morosil + nutrition advice: Participants will take one 500mg capsule (containing Caralluma fimbriata extract) and one 250mg capsule (containing Morosil) orally 30 minutes before meals twice daily for 16 weeks. Participants will also receive nutrition advice in a one on one nutrition consultation with a nutritional therapist for 30-45 minutes, fortnightly for 16 weeks. The recommendations will be based on the Australian Dietary Guidelines for Adults.</interventions>
    <comparator>The placebo capsules will contain 100% maltodextrin. The placebo capsules will be opaque and indistinguishable in appearance, size, texture and smell from the capsules with the active ingredient. The taste of the capsules will be identical as the capsules with the active ingredient provided that they are swallowed whole as instructed. </comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Anthropometric measurements including body weight, height, body mass index, waist circumference, hip circumference, waist to hip ratio, percentage body fat, bone mineral mass, lean body mass and girth/ circumference measurments.</outcome>
      <timepoint>Anthropometric measurements including body weight, height, body mass index, waist circumference, hip circumference &amp; waist to hip ratio will be conducted pre and post intervention and fortnightly during the intervention.
Percentage body fat, bone mineral mass, lean body mass and girth/ circumference measurments will be conducted pre and post intervention.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Blood sample analysis of obesity markers including adipocytokines and lipid profile</outcome>
      <timepoint>Pre and post intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Appetite test via the visual analogue scales (VAS) method and food intake assessment via 3 day food diaries &amp; food freqency questionnaire.</outcome>
      <timepoint>Pre and post intervention for appetite test and food frequency questionnaire. Fortnightly collection of food diaries during the 16 week period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Basal metabolic rate (BMR) will be measured using the metabolic cart (closed circuit spirometry) </outcome>
      <timepoint>Pre and post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physcial activity assessment via physcial activity questionnaire, physical activity diary, accelerometer.</outcome>
      <timepoint>Pre and post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure and heart rate will be measured in a seated position using an automated digital BP monitor </outcome>
      <timepoint>Fortnightly during the 16 week intervention period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Continuous glucose monitoring</outcome>
      <timepoint>Pre and post intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria: Overweight or obese (BMI &gt;25), waist circumference of &gt; 94 cm (male), &gt;80 cm (female), Age: 20-60 years, male or female.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria: Cigarette smoker, hypertension, all types of heart, Liver and kidney disease, pregnancy, lactating, Type 1 diabetes and weight loss medication.

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>12/03/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Victoria University</primarysponsorname>
    <primarysponsoraddress>McKechnie Street
St Albans,
PO BOX 14428
Melbourne, Victoria 8001 </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Victoria University</fundingname>
      <fundingaddress>McKechnie Street
St Albans,
PO BOX 14428
Melbourne, Victoria 8001 </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A 16 week intervention using encapsulated Caralluma fimbriata extract and Morosil extract in combination with lifestyle intervention to investigate whether or not Caralluma fimbriata extract and Morosil extract decrease the risk factors of metabolic sydrome</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Victoira University Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Victoria University
PO Box 14428
Melbourne VIC 8001 </ethicaddress>
      <ethicapprovaldate>11/02/2013</ethicapprovaldate>
      <hrec>HRETH 12/264</hrec>
      <ethicsubmitdate>2/10/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Xiao Su </name>
      <address>College of Health &amp; Biomedicine, Victoria University, McKechnie Street, St Albans, PO Box 14428, Melbourne, VIC 8001 </address>
      <phone>+61 3 9919 2318</phone>
      <fax />
      <email>xiao.su@vu.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Katie Astell</name>
      <address>College of Health &amp; Biomedicine, Victoria University, McKechnie Street, St Albans, PO Box 14428, Melbourne, VIC 8001</address>
      <phone>+61 413 974 652 </phone>
      <fax />
      <email>katie.astell@live.vu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Katie Astell, Xiao Su, Michael Mathai</name>
      <address>College of Health &amp; Biomedicine, Victoria University, McKechnie Street, St Albans, PO Box 14428, Melbourne, VIC 8001</address>
      <phone>+61 3 9919 2318; +61 3 9919 2211 </phone>
      <fax />
      <email>katie.astell@live.vu.edu.au or xiao.su@vu.edu.au or michael.mathai@vu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Katie Astell</name>
      <address>College of Health &amp; Biomedicine, Victoria University, McKechnie Street, St Albans, PO Box 14428, Melbourne, VIC 8001</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>